OptiBiotix Health PLC Market launch for LPLDL® capsules in Germany (0645M)

TIDMOPTI

RNS Number : 0645M

OptiBiotix Health PLC

26 July 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Market launch for LP(LDL) (R) capsules in Germany

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LP(LDL) (R) capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherheit und Verbraucherschutz (BVL)" and commenced commercial sales to pharmacies in Germany on 24 July 2017.

This announcement follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH ("HLH") announced on 15 June 2017. HLH will market capsules containing LP(LDL) (R) under the brand name Lactobact(R) LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform. Sales revenues are difficult to estimate in this new and developing market but are likely to be in the low to mid six figure in the near term growing as HLH builds market presence.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to see the first sales of our LP(LDL) (R) strain in products available to consumers in Germany. We hope this will be the first of many product launches of multiple formulations and presentations of LP(LDL) (R) as the active component in a wide range of pharmaceutical and consumer products around the world. HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe's leading suppliers of probiotics to the pharmacy market. Establishing early sales of LP(LDL) (R) to pharmacies with HLH helps substantiate the credibility in the science behind LP(LDL) (R) to build the brand and acceptance in the larger consumer healthcare markets."

For further information, please contact:

 
 OptiBiotix Health plc                                                   www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                                Contact via 
                                                                             Walbrook below 
 
 Cairn Financial Advisers LLP (NOMAD)                                         Tel: [phone] 
                                                                                       0880 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                                           Tel: [phone] 
                                                                                       0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke / Abigail Wayne (Corporate 
  Broking) 
 
 Walbrook PR Ltd                            Tel: [phone] or [e-mail] 
 Anna Dunphy                                                                 Mob: [phone] 
                                                                                        001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUVAVRBVABUAR

(END) Dow Jones Newswires

July 26, 2017 02:00 ET (06:00 GMT)